Expert Company devoted to Hematological Cancers

- **Our Mission**: Provide Efficient Treatment Solutions for Patients with **Precision Medicine Approaches**.
- **Our Strengths:** >20 Years Expertise in **Multiple Myeloma**, **Unique Cellular Models**, **Patented Methodologies** to the Identification of **Predictive Biomarkers**, and **Customized Services**.

OUR MODELS

Panel of Unique Hematological Cancer Cell Lines



- **Multiple Myeloma (MM) (40 cell lines):**
  - **Representative of the Heterogeneity** of MM Disease[1,A].
  - **Characterized by RNAseq, Exome seq, ChiPseq, SNP…**
  - **Profile of Response to 20 Molecules: IC50s.**
  - **Fully Characterized Panel of Treatments Resistant Cell Lines.**
- **Diffuse Large B-Cell Lymphoma (DLBCL) (20 cell lines)**
- **Acute Myeloid Leukemia (AML) (10 cell lines)**



Collection of Primary Cells from Patients

- **MM samples**
- **All Hematological Malignancies**

- **Diagnosis and Relapse.**
- Biological and Clinical Data.
- Bone Marrow, Blood, Plasma, RNA, DNA of Normal and Tumoral Cells.
- Gene Expression Profiling of Tumoral Cells.

Unique *in vitro* Model of Human Plasma Cell Differentiation

- **Multi Step Culture[2,3,4] Characterized** (Memory B cells, Pre-Plasmablasts, Plasmablasts, Plasma cell, Long lived Plasma cell).
- **Drug Effect in Normal Plasma Cell Generation[5].**

Development of Predictive Biomarkers

1. ***In vitro*** **Treatment of Cell Lines.**
2. **RNAseq and Analyzis of Deregulated Genes.**
3. **Integration of Genomic and Clinical Data.**
4. ***In vitro*** **Biomarker Validation using Primary Cells.**

Published[6,7,8,9,10,11]
And Patented[B,C,D,E,F,G,H,I,J].

Patents/Publications

Patents: A. n°10305892, 2010; B. EP12306141.8, 2012, WO2014056928; C. EP12306225.9, 2012, WO20144044848; D. EP14305404, 2014; E. EP14306201, 2014; F. EP16305682, 2016; G. EP16305651, 2016; H. EP16306436.3, 2016; I. EP17306503.8, 2017; J. EP18305136, 2018.

Publications: 1. Moreaux et al. Haematologica, 2011; 2. Jourdan et al. Blood, 2009; 3. Jourdan et al. Blood, 2010; 4. Kassambara et al. NAR, 2017; 5. Jourdan et al. Oncotarget, 2016; 6. Moreaux et al. Mol Cancer Ther, 2012; 7. Moreaux et al. BJC, 2013; 8. Moreaux et al. BJH, 2013; 9. Kassambara et al. Oncotarget, 2014; 10. Bret et al. Oncotarget, 2012; 11. Bruyer et al. BJC, 2018.

OUR SERVICES

❑ Pharmaceutical Companies ❑ Biotechnology Companies ❑ CROs ❑ Academics

Find and Validate New Therapeutic Targets

Analyze of your Targets Expression

- **Genomic Analyzes in Different Cohorts** of Patients with Hematological Malignancies (Genomic and Clinical Data).
- Analyzis of the **Prognostic Value** of your targets (Survival Analyzis).
- **Validation at the Protein Level** using Flow Cytometry.

In vitro Cytotoxicity Studies



In Hematological Cell Lines

- **Drug Screening**
- *In vitro* **Cell Growth Inhibition (IC50).**
- **Cell Cycle, Apoptosis, Clonogenic Assays.**
- **Synergistic Drug Combinations.**
- Effect on **Drug Resistant** Cell Lines.
- Correlation of the Drug Response with **Mutations and Gene Expression Profiling.**

In Primary Samples of Patients with Hematological Malignancies

- *In vitro* **Viability of Primary Tumor Cells co-cultured with their Bone Marrow Microenvironment.**
- Flow Cytometry Assays to Investigate **NK mediated Lysis** of your **Antibody.**

In Normal Human Plasma cell Generation

- Effect in Normal Plasma Cells and in Different Stages (pre-Plasmablasts, Plasmablasts, Plasma Cells).

Biomarkers

Biomarkers to Predict Drug Response

- **RNAseq** and Gene Expression Profiling.
- **Integration of Genomic and Clinical Data** from Patients Cohorts.
- **Identification of Biomarkers.**
- ***In vitro* Validation using Primary Samples** from Patients.

LAUREAT INNOVATION 2016

18e CONCOURS NATIONAL D'AIDE À LA CRÉATION D'ENTREPRISES DE TECHNOLOGIES INNOVANTES

Diag2Tec, Cap Omega,
Rond Point Benjamin Franklin
CS39521 34960 Montpellier Cedex 2
FRANCE

contact@diag2tec.com
www.diag2tec.com